- Home
- FENC vs TLSI Comparison
FENC vs TLSI Comparison
Compare FENC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- TLSI
- Stock Information
- Founded
- FENC 1996
- TLSI 2010
- Country
- FENC United States
- TLSI United States
- Employees
- FENC N/A
- TLSI N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- TLSI Medical Specialities
- Sector
- FENC Health Care
- TLSI Health Care
- Exchange
- FENC Nasdaq
- TLSI Nasdaq
- Market Cap
- FENC 156.9M
- TLSI 160.4M
- IPO Year
- FENC 2001
- TLSI N/A
- Fundamental
- Price
- FENC $5.53
- TLSI $5.50
- Analyst Decision
- FENC Strong Buy
- TLSI Strong Buy
- Analyst Count
- FENC 2
- TLSI 6
- Target Price
- FENC $14.00
- TLSI $11.75
- AVG Volume (30 Days)
- FENC 126.0K
- TLSI 68.4K
- Earning Date
- FENC 05-13-2025
- TLSI 03-27-2025
- Dividend Yield
- FENC N/A
- TLSI N/A
- EPS Growth
- FENC N/A
- TLSI N/A
- EPS
- FENC N/A
- TLSI N/A
- Revenue
- FENC $47,538,000.00
- TLSI $29,431,000.00
- Revenue This Year
- FENC $2.68
- TLSI $55.43
- Revenue Next Year
- FENC $71.63
- TLSI $50.09
- P/E Ratio
- FENC N/A
- TLSI N/A
- Revenue Growth
- FENC 123.69
- TLSI 58.99
- 52 Week Low
- FENC $3.96
- TLSI $3.50
- 52 Week High
- FENC $11.29
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- FENC 30.64
- TLSI 51.83
- Support Level
- FENC $6.25
- TLSI $5.23
- Resistance Level
- FENC $6.90
- TLSI $5.72
- Average True Range (ATR)
- FENC 0.36
- TLSI 0.34
- MACD
- FENC -0.09
- TLSI 0.01
- Stochastic Oscillator
- FENC 4.20
- TLSI 76.60
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.